Sam Konduros

  • Sam Patrick posted an article
    Biopharma research is an important source of jobs, tax revenue and research spending in SC see more

    New findings show biopharma research companies a source of jobs, tax revenue and research spending in state

     

    GREENVILLE, S.C., October 4, 2018 – This week, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 572 active clinical trials in the South Carolina, and the life science industry supports 29,500 high-quality jobs and contributes $7.9 billion to South Carolina’s economy. These clinical trials can be responsible for more than half of the $2.6 billion average cost of developing one new medicine. They are investigating some of the biggest health care challenges South Carolinians face, including arthritis, cancer, diabetes, cardiovascular disease, and Alzheimer’s disease.

    The report, titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” was released at a press event held at the Westin Poinsett today, which featured a panel discussion including researchers and executives from the Greenville Health System, KIYATEC, the Hollings Cancer Center at MUSC, and the Greenwood Genetic Center, moderated by SCBIO President and CEO, Sam Konduros.

    “Clinical trials offer patients novel medical treatments right here in the Palmetto State, while also allowing biopharma research organizations to innovate and grow,” said Konduros. “Across South Carolina, the life sciences and healthcare industries have had a profound impact on our economy and citizens, that continues to rapidly increase.”

    Clinical trials are a vital component of bringing new life-saving drugs and treatments to market. On average, it takes approximately a decade for new medicines to go through the rigorous Food and Drug Administration (FDA) approval process. Only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted or are currently conducting more than 4,700 clinical trials in South Carolina. In 2013 alone, the nearly 1,100 active clinical trials in the state generated an estimated economic impact of $540 million.

    “One of the most important things we want people to understand about medicine development is that clinical trials rely on patient participation,” said Nick McGee, Director of Public Affairs for PhRMA. “It’s incredibly important that patients are aware of ongoing trials and learn how they can help become part of finding a cure for the toughest chronic conditions and diseases we face today.”

    In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations combined. In South Carolina, of the 572 open clinical trials involving the biopharmaceutical research industry, the University of South Carolina Medial School is collaborating on more than 143 clinical trials and the Medical University of South Carolina is collaborating on more than 142.

    “Many top research and medical universities call South Carolina home and are centers of innovation,” Bob Quinn, Executive Director of the South Carolina Research Authority, said. “Maintaining strong partnerships between our universities and life science companies allows us to foster developments right here in South Carolina that can then help save lives far beyond our state lines.”

    You can read the complete report, “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” here.

    ###

    About PhRMA
    The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $71.4 billion in 2017 alone.

    About SC BIO
    SCBIO is South Carolina’s investor-driven public/private economic development organization focused on building, advancing, and growing the life sciences industry in the state.  With an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products that make a difference across the Palmetto State and around the world.  Visit us at SCBIO.org.

  • Sam Patrick posted an article
    Life sciences in South Carolina is big business -- and getting bigger by the day. Read why... see more

    In this article published simultaneously in Charleston Business Magazine, Columbia Business Magazine and Greenville Business Magazine, SCBIO CEO Sam Konduros paints a picture of the diversity of the rapidly-growing life sciences industry, and why the future is exceedingly bright -- and getting brighter -- as the $11.4 billion industry soars to new heights across South Carolina.

     

    Life sciences in South Carolina spans a diverse spectrum—from major pharmaceutical companies to globally known medical device companies.

    It encompasses start-ups and early stage innovation companies and embraces prestigious research universities and acclaimed health care systems employing some of America’s finest minds. It includes research and medical labs, bioscience-related distribution, even Bio-Ag tied to the state’s historical agricultural segment. Click to read complete article...

  • Sam Patrick posted an article
    Top life sciences leaders from across the state have been named to the SCBIO Executive Committee see more

    Leadership team provides strategic blend of economic development, industry, higher education expertise

     

    GREENVILLE, SC – January 17, 2019 – SCBIO has announced its 2019 Executive Committee following formal confirmation at the life science organization’s December 2018 meeting in Columbia.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve a second term as SCBIO’s 2019 Board Chair.

    Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by more than 300% and increased shipped product to one billion doses each of the last seven years.  Nephron constructed a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.  The organization was honored as an inaugural winner of the South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry in October, 2018.

    Joining Ms. Kennedy on the SCBIO Executive Committee will be Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Vice Chair; Michael Rusnak, Executive Director of the Medical University of South Carolina Research Foundation as Treasurer; and Josh Ridley, Global Business Development Director of ZEUS as Secretary.  

    Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Heather Simmons Jones, CEO of the Greenwood Partnership Alliance as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; Adam Hoots, Life Sciences Market Leader for DPR Construction as Talent/Workforce Officer; and Sam Konduros, President and CEO of SCBIO. 

    Recognized for completing their terms as contributing members of the SCBIO Executive Committee were former Vice Chair Craig Walker, executive with Hitachi Healthcare Americas, and former Secretary Kathryn Becker, Principal with Translational Science Solutions LLC.

    SCBIO President and CEO Konduros praised the Executive Committee noting, “With the critically important efforts we are undertaking to advance pharmaceuticals, life sciences R&D, biotech, med-tech, and the health IT industries in South Carolina, we require strong, expert leadership from across the state, fully integrating our business, education and economic development sectors. These diverse leaders who represent the width and breadth of our state and industry will effectively champion our vision of building the business of life sciences in South Carolina for years to come.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    The Executive Committee and Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

    For additional information on SCBIO, visit www.SCBIO.org

  • Sam Patrick posted an article
    SCBIO's Konduros named to GBM's 2018 Most Influential, Hall of Fame see more

    Greenville Business Magazine celebrates another year of honoring the region’s most influential people. The selection of our 50 individuals is a result of staff research and community nominations.

    We are also celebrating our fifth year of selecting entrants for our Hall of Fame. This year, we’re adding eight new members who have continued to make a lasting impact on the Upstate, including SCBIO President & CEO Sam Konduros.  Read on to enjoy the complete story.

  • Sam Patrick posted an article
    Building the business of life sciences in South Carolina has become the call to action of SCBIO... see more

    Building the business of life sciences in South Carolina has become the call to action and theme of the 2017 annual conference of the S.C. Biotechnology Organization (SCBIO).  The rapidly evolving statewide industry association is featured in this September 2017 issue of Charleston Business Magazine, and will be featured in October 2017 issues of Columbia Business and Greenville Business as well.  Click here for the full article.

  • Sam Patrick posted an article
    Southeastern life science organization join forces to promote entire region see more

    SCBIO and six additional Southeastern U.S. life science and medtech groups are joining forces to better promote and advocate for the region.

    The Southeastern Medical Device Association (SEMDA) on Wednesday announced the formation of an alliance with six individual state medtech and life science advocacy groups: BioAlabama, Bio Florida, Georgia Bio, ncbio, Life Science Tennessee and SCBIO.

    “Industry and academic partners simply cannot invest enough in each individual state’s bio advocacy organization — nor travel to each organization’s annual event every single year,” SEMDA executive director Jason Rupp said in a news release.

    “But they can come to SEMDA, where the entire region gathers every year bringing their leading investors, academic and industry partners including the best of their young, innovative, investable companies,” Rupp said.

    No single state in the Southeastern U.S. can match the medical device and life science industry strength of the nation’s major hubs in California, Minnesota and Massacusetts. But taken together, the region is more competitive, according to industry advocates there.

    “We are strongest as a region,” said Russell Allen, president and CEO of Georgia Bio. “If we are to advance medical technologies to improve care, reduce healthcare costs and create new jobs, our state associations must work closely together to connect innovators and share resources.”

    The announcement was made at the inaugural 2018 SEMDA Medtech Conference May 2-4 in Greenville, S.C.

  • Sam Patrick posted an article
    Industry subject matter experts to cover what businesses need to know about state industry see more

    GREENVILLE, SC – February 14, 2018 – SCBIO will host a half-day program March 14, 2018 -- South Carolina Life Sciences Boot Camp: Essentials of a Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.

    To be held at the University of South Carolina’s Arnold School of Public Health in Columbia, the program will run from 8:30 a.m. until 12:30 p.m. and will feature a light breakfast followed by presentations from over half a dozen noted life sciences industry leaders.  Confirmed presenters and their topics are:

    • Burnie Maybank, Author of the SC Life Sciences Act; Partner, Nexsen Pruet, “Life Sciences industry Economic Development Incentives”
    • Stephanie Yarbrough, Partner, Womble Bond Dickinson, “M&A 101 in the Life Sciences Space”
    • Kathryn Cole Becker, Principal, Translational Science Solutions, “FDA 101 for Medical Devices”
    • Jeff Stover, Partner, Haynsworth Sinkler Boyd, “IP Essentials for Life Sciences”
    • John Osborne, Partner, Good Growth Capital, “Introduction to Life Science Innovation & Entrepreneurship”
    • Public Policy Hot TopicsSpeaker to be announced

    Attendance is free to SCBIO members and employees of SCBIO member companies, and available for only $75 to Non-Members.  Advance registration is required, and space is limited.  To register, visit www.SCBIO.org/Events

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO’s diverse membership is leading research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

    For additional information on SCBIO, visit www.SCBIO.org.

  • Sam Patrick posted an article
    SCBIO has named its 2018 Board of Directors and Board Chair see more

    SCBIO has announced its 2018 Board of Directors and Executive Committee following formal confirmation at the life science organization’s December 2017 meeting in Columbia.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve as SCBIO’s 2018 Board Chair.

    Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by 300% and increased shipped product to one billion doses each of the last seven years.  Nephron recently built a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.

    Joining Ms. Kennedy as officers on the SCBIO Executive Committee will be Craig Walker, CEO of VidiStar LLC as Vice Chair; Michael Rusnak, Executive Director of the Medical University of South Carolina Research Foundation as Treasurer; and Kathryn Cole Becker, Principal of Translational Science Solutions as Secretary.  Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; and Sam Konduros, President and CEO of SCBIO.  Immediate Past Chair, Erin Ford, who now serves as the organization’s inaugural Vice President, was honored for her extraordinary board service during the December Board meeting.

    Also elected to the 22-member Board of Directors for SCBIO are Darralyn Alexander, President of Reimbursement Strategies LLC; Mandy Brawley, Deputy Director of the South Carolina Department of Commerce; Jerry Chang, Vice President of Business Development for BioD; Matthew Couvillion, Attorney with the Wyche Law Form; J.J. Darby, State Government Affairs Leader for Johnson & Johnson Services; Tressa Gardner, Associate Vice president of the Southeastern Institute of Manufacturing and Technology at Florence-Darlington Technical College; and Mike Graney, Vice President  for Global Business Development of the Charleston Regional Development Alliance.

    Completing the 2018 Board of Directors for SCBIO are Chad Hardaway, Associate Director of the Office of Economic Engagement at the University of South Carolina; Willard Harms, VP of Medical Affairs for Blue Cross Blue Shield of South Carolina; Dr. Martine LaBerge, Chair of Clemson University’s Department of Bioengineering; Marc Metcalf, Business Recruitment Officer of the Upstate SC Alliance; Kathy Phlegar, President of Phlegar & Associates; Christine Dixon Thiesing, Director of Academic Programs for the South Carolina Research Authority; and Courtney Warren, Life Sciences Practice Chair for Marsh & McLennan Agency.

    SCBIO President and CEO Konduros praised the Board and Executive Committee noting, “With the important work we are undertaking to actively advance life sciences R&D, biotech, med-tech, and digital health industries in South Carolina, we require strong, expert leadership from all across the state, fully integrating the business, education and economic development sectors. I am confident that these diverse leaders who reside in communities ranging from Murrells Inlet to Florence in addition to Greenville, Columbia, and Charleston, will effectively champion our vision of building the business of life sciences in South Carolina in 2018 and for years to come.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    The Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

  • Sam Patrick posted an article
    SCBIO has named Erin Ford as the organization's first VP see more

    SCBIO’s executive committee announced today that Erin Ford, currently the director of sales at Anderson-based Poly-Med Inc. and Chair of the Board of Directors of the South Carolina Biotechnology Industry Organization (SCBIO), is joining the non-profit life sciences industry organization as its inaugural Vice President.

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    “Erin is an extraordinarily talented, multi-faceted executive with magnetic relationship-building skills, along with being a proven leader,” said SCBIO President/CEO, Sam Konduros.  “As I was vetting and interviewing a number of extremely worthy candidates for this critical executive position, it occurred to me that our board chair was the absolute perfect fit, and I felt humbly compelled to ask Erin to consider exploring the role.  To my and the Executive Committee’s great delight, she ultimately committed to bring her signature career to SCBIO on a full-time basis starting January 2nd.  We are extremely fortunate to have such a knowledgeable and seasoned pro like Erin join the executive team and hit the ground running in 2018, following a year of her outstanding leadership as our board chair.”

    Ms. Ford departs Poly-Med, a global innovation company that is developing absorbable polymers and constructs for the medical device industry, for her new role at SCBIO, where she will work closely with the CEO on various corporate strategies emanating from the organization’s 3 statewide offices.  Her comprehensive responsibilities will include serving as primary lead for SCBIO’s business operations, championing investor relations and existing industry strategies, and spearheading major integrated marketing initiatives.

    She previously served as a business recruitment officer at the Upstate SC Alliance, where she was the main point of contact for life sciences companies interested in expanding or locating in Upstate South Carolina, and gained in-depth economic development experience. While at the Upstate Alliance, Ms. Ford served as an ex-officio SCBIO board member from 2013-2015, and led a regional biosciences task force comprised of industry executives from across the region. She also has extensive television experience as a documentary producer and sportscaster, and received her B.A. in Communication from La Salle University in Philadelphia.

    "SCBIO presents a unique career opportunity to work in an arena whose constituent members and companies make a tangible difference in the quality of people's lives," said Ms. Ford. "Our hundreds of members include academic institutions, biotech companies, service providers, thought leaders, and economic development groups whose members are leading the research and development of innovative healthcare, industrial and environmental biotechnology and med-tech products that can transform and extend people’s lives.  While I have loved my time at Poly-Med, which served as an invaluable life science industry experience for my new career path with SCBIO, this unique opportunity to touch lives and grow South Carolina's knowledge economy was simply too powerful to pass up."

    Ms. Ford joins SCBIO's recently named President and CEO Sam Konduros atop the growing organization's leadership team.  Konduros, also a former SCBIO board member, assumed the leadership reins of the group earlier this year after departing Greenville Health System, where he ran the Research Development Corporation forging industry partnerships, developing economic development strategies, and helping doctors take their inventions to market. Previously, he was the first president of the Upstate SC Alliance, the Upstate region’s economic-development agency.

    The addition of Ms. Ford occurs as SCBIO continues to flex new muscles to advance and grow the business of life sciences in South Carolina.  It comes on the heels of the organization's recent restructuring and rebranding efforts, and its highly successful annual conference, which drew hundreds of industry leaders, national executives, academics, economic development organizations, government officials and others to Charleston October 24-26.  The organization has already attained record membership and investor levels, and recently formed a partnership with the South Carolina Department of Commerce to develop and implement strategic growth recommendations for the state’s fast-expanding industry.

    "This industry is at a critical time for accelerating our growth and impact in South Carolina and well beyond," said Ms. Ford.  "When you have such a unique opportunity, you have to seize the day and make positive things happen.  That's our goal."

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

  • Sam Patrick posted an article
    Governor honors Konduros during keynote address at packed life sciences conference see more

    SCBIO CEO Sam Konduros was presented with the Order of the Palmetto, the state's highest civilian honor, during SCBIO's annual conference at the Gaillard Center in Charleston last week.

    Governor McMaster was one of the featured keynote speakers at the gathering, where he extolled the state's virtues as a growing life sciences cluster.  Following his comments, he surprised Konduros and the crowd of nearly 300 life sciences executives and leaders by presenting the honor, citing Konduros’ long service to the state. 

    The Order of the Palmetto is the highest civilian honor in the State of South Carolina and is awarded for extraordinary lifetime service and achievements of national or statewide significance. The selections are screened and vetted by a bipartisan committee and then forwarded on to the governor for final consideration.  Governor John C. West presented the first Order of the Palmetto in the summer of 1971 as a way to recognize outstanding achievements, service, and contributions to South Carolina.

    Konduros, who became CEO at SCBIO about six months ago, says he was humbled by the honor.

    "I have had a love affair with South Carolina for as long as I can remember, so to receive the state's highest civilian honor directly from the governor -- in the midst of the SCBIO Annual Conference -- was one of the most humbling and overwhelming experiences of my life," he said. "I was beyond surprised, and am extraordinarily grateful."

    Konduros began serving as President and CEO of SCBIO (South Carolina Biotechnology Industry Organization) in Spring 2017, and has focused on leading the statewide organization to its next level of development. SCBIO is committed to building, advancing, and growing the life sciences industry in South Carolina, working closely with strategic partners from industry, academia, and the public/private sector - including complementary local, regional, and state economic development agencies such as the SC Department of Commerce.  SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.

    Konduros has also served as Founder of SK Strategies, LLC - a Greenville-based consulting firm that specializes in economic development, public-private partnerships, integrated marketing and business development strategies for such clients as CU-ICAR, Clemson University, Greenville Health System, and KENTWOOL.  He formerly served as Executive Director of the Greenville Health Research Development Corporation (RDC), as well as Senior Project Manager for the SC Department of Commerce, Alfmeier Corporation’s Executive VP for North America, and Founding CEO of Upstate SC Alliance in past years.

    A licensed attorney since 1989, Konduros currently serves as board member and past chair of the Cancer Society of Greenville County, South State Bank Greenville Advisory Board, Palmetto Conservation Foundation board, and is a past executive committee/ and board member of the SC Chamber of Commerce.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    For additional information on SCBIO, visit www.SCBIO.org

  • Sam Patrick posted an article
    Top speakers and brands are committing to attend SCBIO 2017 in Charleston this October; have you sig see more

    BIO global CEO Jim Greenwood will join South Carolina Governor Henry McMaster as featured luncheon speakers on the first full day of SCBIO 2017 – the annual conference bringing top leaders and executives from organizations across the life sciences industry to Charleston, South Carolina October 24–26.

    Mr. Greenwood will be addressing the gathering with a keynote presentation entitled “Global Trends for the Life Sciences Industry – and Implications for South Carolina” at lunch on October 25.  South Carolina Governor Henry McMaster will follow with a presentation entitled “Life Sciences Powered by Public/Private Partnership – A Strategic View from the Statehouse.”

    Dozens of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, and industry supporters from across America have already committed to attend SCBIO 2017 at Charleston’s Gaillard Auditorium, organizers confirmed today.  Among the committed speakers and panelists are Nephron Pharmaceuticals CEO Lou Kennedy, MUSC President David Cole, Clemson University President Jim Clements, USC President Harris Pastides, Medpoint CEO Chuck Crumpton, Belimed CEO Joseph McDonald, AVX Health Division executive Robert Fairey and numerous others.

    Themed “Building the Business of Life SCiences in SC”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  While space is limited and advance registration is required, interested attendees can still register at http://scbio2017.eventbrite.com.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2017 kicks off Tuesday evening with a Welcome Reception for conference registrants, speakers and sponsors on the rooftop terrace of the Grand Bohemian Hotel.  Wednesday will feature a full day of sessions beginning at breakfast with a greeting by Charleston Mayor John Tecklenburg and continuing through an evening reception.  The conference will wrap up Thursday at lunchtime. 

    “The life sciences industry has become a major driver of South Carolina’s economy,” noted South Carolina Secretary of Commerce Bobby Hitt recently. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, we know that this sector has tremendous growth potential, and we’re excited to be partnering with SCBIO to help life sciences continue to advance in South Carolina.”  SC Commerce is a Founding Partner of SCBIO and of the Conference.

    Among the leading biotech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, Softbox, NCGS and SEMDA.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are attending, as is Greenville Health System and economic development entities including SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    For additional information on SCBIO, visit www.SCBIO.org.  To register for SCBIO 2017, visit http://scbio2017.eventbrite.com

  • Ty Kourlas posted an article
    SCBIO named Sam Konduros, as the new president and CEO of the statewide not-for-profit entity see more

    The South Carolina Biotechnology Industry Organization (SCBIO) named Sam Konduros, a business leader and biomedical and economic development consultant, as the new president and CEO of the statewide not-for-profit entity. SCBIO represents and catalyzes innovators in medicine, medical devices and biomaterials.

    Konduros, a member of the SCBIO board, is the founder of SK Strategies LLC launched in 2004, and has led or consulted numerous state economic development efforts. He also served as executive director of Greenville Health System’s Research Development Corporation from 2014 to 2016.

    “Sam’s strengths in knowing the biotech sector and his deep experience in business and economic development were compelling,” said Erin Ford, Chair of SCBIO.  “The board was won over by his vision for the growth of SCBIO.”

     

    As executive director for the GHS RDC, Konduros worked to facilitate tech transfer, attract new biomedical companies and grow collaborations between clinicians, researchers, and health educators while nurturing startups in shared lab space. He also chaired the healthcare system’s IP Committee, and helped develop the concept for a new life sciences innovation district referred to as the IMED Innovation Corridor.

    “I greatly appreciate the SCBIO board’s passion for serving and advancing South Carolina’s rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward,“ Konduros said. “I am highly motivated to get officially started in this exciting new role in late April, and I am confident we will have some dynamic and innovative new initiatives to announce by the time our annual conference takes place in Charleston Oct. 25-26.”

    Konduros also served as a multi-year consultant to help forge the Clemson University’s International Center for Automotive Research (CU-ICAR).  He was the founding president and CEO of The Upstate SC Alliance. Konduros is a former Cancer Society chairman, Greenville Chamber chairman, and SC Chamber of Commerce executive committee member. He has a law degree from the University of South Carolina and undergraduate degree from Clemson.

    Read more at....

    https://upstatebusinessjournal.com/news/konduros-new-scbio-president-ceo/ 

  • Ty Kourlas posted an article
    S.C. life science group, SCBIO, names new leader as young industry gains attention. see more

    A longtime booster of the Upstate's economy is taking on a new challenge with a broader reach and a narrower focus: growing South Carolina's nascent life sciences industry.

    SCBIO - a trade group representing biotechnology companies - has named Sam Konduros its next president and CEO, a move that comes as state officials increasingly eye the business as a target for South Carolina's economy.

    Konduros, a former SCBIO board member, comes to the group from the Greenville Health System, where he ran an office that helped doctors take their inventions to market. Previously, he was the first president of the Upstate SC Alliance, the region's economic-development agency.

     

    At Greenville-based SCBIO - short for the S.C. Biotechnology Industry Organization - he'll be tasked with helping to grow an industry that's only recently taken shape here.

    The life sciences cover a broad mix of companies, from firms developing new drugs and researchers inventing medical devices to the manufacturers that make them. And while the state has a toehold into most corners of the sector, it's still relatively small here, employing about 17,500 workers statewide.

    "It's a young industry that has the opportunity to grow into a powerful economic bookend for South Carolina," Konduros said.

    The group's outgoing president, Wayne Roper, is credited with helping to map out its extent. His last task in the role is to finish a study backed by the S.C. Commerce Department outlining what life science companies are in the state, and where it's best poised to grow.

    When he starts next month, Konduros's job will be to take those findings and bring them to fruition. The issues facing the life sciences industry, meantime, aren't so different from the state's technology sector as a whole.

    New companies face challenges finding investments to fund their early operations before revenue rolls in. And the state is often overlooked amid regional powerhouses like Atlanta and North Carolina's Research Triangle.

    Konduros says he'd like to turn that tide by marketing South Carolina to investors and industry executives - to sell them on the state's research universities and its emerging startup community. And he expects to take that message to the state's General Assembly, too.

    Meantime, economic-development agencies have warmed to the sector recently. At the Commerce Department, the state Council on Competitiveness is now targeting biotech as a growth area for the state. And in the Lowcountry, the Charleston Regional Development Alliance is studying the sector as well.

    "We're at a critical time for that growth," said Erin Ford, SCBIO's board chair. "When you have change it's an opportunity to really listen and take stock."

     

    Read more at...

    http://www.postandcourier.com/business/s-c-life-science-group-names-new-leader-as-young/article_4eda6e1c-09c3-11e7-8626-9fe278c1fa12.html